**Supplementary Table 1**. Characteristics of included randomized controlled trials in the meta-analysis which compared the efficacy and safety PD-1/PD-L1 inhibitor-based immunotherapy combined with chemotherapy and other treatments on unresectable locally advanced or metastatic TNBC.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year | NCT | Masking | Median follow-up time (years) | | Random allocation ratio | Trial duration | Age of ITT participants | | Definition of PD-L1 |
| Treatment | Control | Treatment | Control |
| Bachelot, 2021 | NCT02299999 | none (open-label) | 19.7 (IQR 16.5-22.3) | | 2:1 | 2014.4-2022.12 | 56 (range 27-79) | 56.5 (range 24-77) | Samples of metastatic lesions obtained within 1 year before patient enrollment were assessed for PD-L1 protein expression by immunohistochemistry using the SP142 antibody with ≥1% staining of immune cells |
| Brufsky, 2021 | NCT02322814 | none (open-label) | 8.5 (range 1.6-16.8) | 7.7 (range 0.7-15.7) | 1:1 | 2014.11-2021.9 | 52 (range 26-79) | 55 (range 34-73) | PD-L1-stained tumor-infiltrating immune cells covering > 1% of the tumor area |
| Cortes, 2020 | NCT02819518 | quadruple (participant, care provider, investigator, outcomes assessor) | 25.9 (IQR 22.8-29.9) | 26.3 (IQR 22.7-29.7) | 2:1 | 2016.7-2022.1 | 53 (range 44–63) | 53 (rang 43–63) | PD-L1 CPS ≥1 (The PD-L1 CPS was defined as number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by total number of tumor cells ×100) |
| Miles, 2021 | NCT03125902 | double (participant, investigator) | 9.0 (range 0.5-25.4) | 8.6 (range 0.0-26.1) | 2:1 | 2017.8-2021.12 | 54 (range 22-85) | 53 (range 25-81) | Immune cell PD-L1 expression > 1% of the tumor area, assessed by VENTANA PD-L1 (SP142) immunohistochemistry assay |
| Schmid, 2020 | NCT02425891 | double (participant, investigator) | 18.8 (IQR 8.9-34.7) | | 1:1 | 2015.6-2021.8 | 55 (IQR 46-64) | 56 (IQR 47-65) | PD-L1-expressing immune cell covering > 1% of the tumor area, assessed by VENTANA PD-L1 (SP142) immunohistochemistry assay |
| Winer, 2021 | NCT02555657 | none (open-label) | 31.4 (IQR 27.8-34.4) | 31.5 (IQR 27.8-34.6) | 1:1 | 2015.10-2020.11 | 50 (IQR 43–59) | 53 (IQR 44–61) | PD-L1 CPS ≥1 (The PD-L1 CPS was defined as the number of PD-L1-positive cells (tumour cells, lymphocytes, and macrophages) divided by total number of tumour cells multiplied by 100) |

PD-1/PD-L1: PD-1/PD-L1: programmed cell death protein 1/programmed cell death 1 ligand 1; NA: not available; ITT: intention to treat; PD-L1: programmed death-1; CPS: combined positive score